Table 1 Overview of included studies
Authors | Year | Study design | Population size | Age in years (range) | Breast cancer stage of included patients | Breast cancer types | Breast cancer subtypes |
|---|---|---|---|---|---|---|---|
Abraham et al. | 1996 | Prospective | 39 | 50 (31–73) | IIa, IIb,IIIa, IIIb | IDC, ILC, mixed ductal and lobular carcinoma | ER, PR |
Esserman et al. | 2001 | Prospective | 33 | 46 (32–75) | IIIa, IIIb, IIIc, to large for breast conserving therapy | IDC, ILC, inflammatory | ER, PR |
Rieber et al. | 2002 | Prospective | 58 | 51 (27–72) | Not reported | IDC, ILC, DCIS, mucinous carcinoma, ductolobular carcinoma | Not reported |
Partridge et al. | 2002 | Prospective | 52 | 47 (29–72) | Not reported | Not reported | Not reported |
Cheung et al. | 2003 | Prospective | 33 | 45 (29–63) | Not reported | IDC, ILC, mucinous carcinoma | Not reported |
Denis et al. | 2004 | Prospective | 40 | 48 (29–64) | LABC | Not reported | Not reported |
Warren et al. | 2004 | Retrospective | 67 | 46 (28–62) | Not reported | Not reported | ER, PR |
Martincich et al. | 2004 | Prospective | 30 | 49 (36–65) | II, III, inoperable locally-advanced breast cancer | IDC, ILC | ER, PR |
Schott et al. | 2005 | Prospective | 43 | 48 (26–66) | IIb, IIIa, T1N0/1, T2N0/1 | IDC, ILC, mixed ductal and lobular carcinoma, anaplastic carcinoma | ER |
Yeh et al. | 2005 | Prospective | 31 | 45 (31–65) | IIb,IIIa, IIIb, IIIc | IDC, ILC, mixed ductal and lobular carcinoma, invasvive carcinoma n.o.s. | Not reported |
Belli et al. | 2006 | Prospective | 45 | 54 (30–76) | IIa, IIb, IIIa, IIIb, | IDC, ILC, mucinous carcinoma, tubular carcinoma | ER, PR |
Segara et al. | 2007 | Prospective | 68 | 50 (29–71) | Clinical stage I, II, and III | IDC, ILC, mixed ductal and lobular carcinoma; sometimes DCIS or LCIS present in lesions | ER, PR, HER2 |
Kim et al. | 2007 | Prospective | 50 | 42 (25–68) | IIb, IIIa, IIIb, IIIc | IDC, ILC | ER, PR |
Chen et al. | 2007 | Prospective | 51 | 50 (31–77) | II, III, IV | IDC, ILC | HER2 |
Bhattacharyya et al. | 2008 | Prospective | 32 | 42 (24–60) | >4 cm, large tumours in small breasts, node involvement | Not reported | Not reported |
Moon et al. | 2009 | Prospective | 195 | 46 (not reported) | Not reported | Not reported | ER, PR, HER2 |
Wright et al. | 2010 | Prospective | 48 | 47 (30–72) | IIb, IIIa, IIIb | IDC, ILC, invasive micropapillary carcinoma | ER, PR, HER2 |
Woodhams et al. | 2010 | Prospective | 69 | Not reported | Not reported | IDC, ILC, DCIS, LCIS, mucinous carcinoma, other | Not reported |
Park et al. | 2010 | Retrospective | 53 | 44 (24–65) | IIa,IIb, IIIa, IIIb | IDC, mucinous carcinoma, mixed ductal and lobular carcinoma | ER, PR, HER2 |
De Los Santos et al. | 2010 | Retrospective | 81 | 50 (27–73) | Not reported | IDC, ILC, mixed ductal and lobular carcinoma, carcinoma n.o.s. | ER, PR, HER2 |
Straver et al. | 2010 | Retrospective | 208 | 46 (23–76) | >3 cm and/or N+ | IDC, ILC, carcinoma n.o.s. | ER, PR, HER2 |
Nakahara et al. | 2010 | Prospective | 86 | 48 (24–62) | Not reported | IDC, papillotubular carcinoma, solid-tubular carcinoma, scirrhous carcinoma | ER, HER2 |
Wang et al. | 2010 | Prospective | 43 | 48 (34–69) | II, III | IDC | Not reported |
Dongfeng et al. | 2011 | Prospective | 60 | 55 (not reported) | I, IIa, IIb, IIIa, IIIb, IIIc | IDC, mucinous carcinoma | ER, HER2 |
Fangberget et al. | 2011 | Prospective | 31 | 51 (37–72) | Not reported | IDC, ILC | ER, PR, HER2 |
Guarneri et al. | 2011 | Retrospective | 59 | 48 (30–70) | IIa, IIb, IIIa, IIIb, IIIc | IDC, ILC, other n.o.s. | ER, PR, HER2 |
Loo et al. | 2011 | Prospective | 118 | 46 (23–76) | >3 cm | IDC, ILC, adenocarcinoma n.o.s. | ER, HER2 |
Shin et al. | 2011 | Prospective | 43 | 43 (25–62) | LABC/inflammatory breast cancer and at least N1, or unsuitable for BCT, or skin/chest wall involvement | IDC, micropapillary carcinoma | ER, HER2 |
Lyou et al. | 2011 | Retrospective | 57 | 44 (24–64) | Not reported | IDC, ILC | Not reported |
Chen et al. | 2011 | Prospective | 50 | 49 (28–82) | Not reported | IDC, ILC, invasive cancer with squamous differentiation | ER, PR, HER2, Ki-67 |
Kim et al. | 2012 | Prospective | 55 | 49 (28–82) | IIa, IIb, IIIa, IIIb, IIIc, IV | IDC, ILC, mucinous carcinoma | Not reported |
Kuzucan et al. | 2012 | Retrospective | 54 | 46 (29–63) | Not reported | IDC, ILC, mixed ductal carcinoma with lobular features | ER, PR, HER2, Ki-67 |
Takeda et al. | 2012 | Prospective | 37 | 51 (30–78) | Not reported | Not reported | Not reported |
Shin et al. | 2012 | Retrospective | 90 | 46 (24–68) | IIa, IIb, IIIa, IIIb, IIIc | IDC, ILC, metaplastic carcinoma, micropapillary carcinoma | ER, PR, HER2 |
Hylton et al. | 2012 | Prospective | 216 | 48 (26–68) | T3 tumour of at least 3 cm | IDC, ILC, mixed ductolobular carcinoma, mucinous carcinoma | ER, PR, HER2 |
Park et al. | 2012 | Retrospective | 34 | 44 (27–60) | Tumour size >2 | IDC, mucinous carcinoma, mixed ductolobular carcinoma | HER2 |